Diamond Therapeutics Hires Industry Veteran David Brown, PhD, To Advance Psilocybin Formulation


Brown to lead pharmaceutical development activities at Diamond

TORONTO, July 26, 2021 / PRNewswire / – Black Diamond Therapeutics, Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, today announced the appointment of David Brown, PhD, as Vice President, Pharmaceutical Development.

Brown has an impressive track record, having held leadership positions at leading pharmaceutical companies including Patheon, Teva and Impopharma. He has developed numerous dosage forms, including complex, high barrier-to-entry drug-device combination products for multiple global markets. His broad expertise includes program management; he has carried out projects from pipeline selection and project concept to commercialization. Brown received his doctorate in pharmacy from the School of Pharmacy, University of London.

“With the global mental health crisis and the lack of effective treatment options, the unique characteristics of psychedelics hold the promise of bringing exciting new options to patients with unmet needs,” said Brown.

“I am delighted to join Diamond’s impressive leadership team to work with highly esteemed experts and partners.”

At Diamond, Brown will lead cutting-edge research and development in the formulation of low-dose psychedelics for pharmaceutical use and the synthesis of novel compounds.

It will work closely with leading pharmaceutical manufacturer Dalton Pharma Services, which has an exclusive global partnership with Diamond to supply psilocybin cGMP and other compounds to support clinical trials, research and future business opportunities.

Dalton is one of the few Canadian companies to successfully manufacture psilocybin cGMP for potential use in regulatory submissions. The material already produced is sufficient for Diamond’s needs for its own clinical trials and research.

Dalton is approved by Health Canada, inspected by the FDA and works in accordance with the guidelines of the International Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Brown’s work with Dalton will be instrumental for Diamond as he prepares to begin his clinical trial programs with low-dose psilocybin in United States and Canada.

“At Diamond, we are delighted to have David join the team. The level of expertise he brings to the development of pharmaceuticals will be essential to accelerate our drug development efforts, ”says Judy Blumstock, CEO of Diamant.

About Diamond Therapeutics
Diamond Therapeutics is a psychedelic drug development company based in Toronto. Our mission is to develop new and better therapies for mental health issues by unlocking the promise of psychedelic compounds. Diamond is focused on subperceptive and non-hallucinogenic therapies that have potential for use in a large cohort of patients – maximizing the positive impact that better drugs can have on the global mental health crisis. To learn more about Diamond, visit www.diamondthera.com.

About Dalton Pharma Services
Dalton Pharma Services is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development and manufacturing services. We are FDA inspected, Health Canada approved, and bring over 30 years of experience to every project. We offer fully integrated solutions with an emphasis on speed, flexibility and quality. Our integrated services in one place help us to be adaptable, flexible and profitable. To learn more about our history and capabilities, please visit http://www.dalton.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/diamond-therapeutics-hires-industry-veteran-david-brown-phd-to-further-advance-formulation-of-psilocybin-301340894.html

SOURCE Diamond Therapeutics Inc.


Leave A Reply